Zenith Epigenetics Announces Appointment to Board of Directors

0

CALGARY, Alta., Jan. 31, 2022 (GLOBE NEWSWIRE) — Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its Board of Directors.

Dr. Thompson is an experienced biotech founder and executive having served as CEO of a public company for 22 years. He has served as chairman, director and member of the audit committee of several public company boards (NASDAQ, TSX and CDNX) and has served as a director on the boards of private companies and industry groups (including chairman and President Emeritus of BIOTECanada). He has listed companies on the TSX, NASDAQ and the old Alberta Stock Exchange, as well as successful cross listings (TSX to NASDAQ). Dr. Thompson holds a PhD in Microbiology and Immunology from the University of Western Ontario. Prior to entering the private sector, his research affiliations included work with NASA and the Canadian Space Agency, the United Nations, Colorado State University and the University of Alberta.

“We are very pleased to welcome Dr. Thompson to our Board of Directors, a highly experienced biotech businessman who brings a wealth of varied experience that will help drive Zenith forward,” said Mr. Donald McCaffrey, President and CEO of Zenith.

“I am delighted to join Zenith at such an exciting time in the clinical development of its lead compound ZEN-3694,” said Dr. Thompson. “With such a broad clinical program offering, including multiple promising opportunities to improve the lives of oncology patients, I look forward to seeing what comes next from this impressive program.”

Dr. Thompson’s appointment coincides with the departure of Dr. Eldon Smith from the Board of Directors, effective today. Dr. Smith has served on Zenith’s Board of Directors since its inception in 2013.

“We are immensely grateful for Dr. Smith’s many contributions, advice and expertise over the years, which have greatly helped to move our programs forward. We would like to express our sincere appreciation to him for all his years of service and wish him all the best,” Mr. McCaffrey said.

Clinical Update

Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-screened or enriched patient populations. Our lead compound, ZEN-3694, is under clinical development in several clinical trials:

1. Phase 2b trial in metastatic castration-resistant prostate cancer (mCRPC) in combination with the androgen receptor blocker, XTANDI (enzalutamide):
  • Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC
  • Produced in collaboration with Astellas Pharma and Newsoara Biopharma
  • This study is active and currently recruiting at several sites in the United States and is in the activation phase in China
  • Differentiated study that will focus on addressing a significant unmet need in patients with RA-independent tumors
  • The study rationale and trial design will be presented at the next ASCO Genitourinary Cancer Symposium (February 17-19, 2022)
2. Phase 2b trial in triple negative breast cancer (TNBC) in combination with the PARP inhibitor TALZENNA (talazoparib):
  • Produced in collaboration with Pfizer and Newsoara Biopharma
  • This study is an extension of the ongoing Phase 2 trial and is in the activation phase in the US/EU/China
  • Based on discussions with the US FDA, this phase 2b trial – with a positive outcome – may potentially allow registration of ZEN-3694 via accelerated approval
  • Results from the completed portion of Phase 2 of the trial are expected to be presented at the ASCO Annual Meeting (June 3-7, 2022)
3. Androgen Receptor Independent mCRPC Phase 1b/2 Trial in Combination with Immune Checkpoint Inhibitor KEYTRUDA (pembrolizumab) and XTANDI:
  • Produced in collaboration with Merck, University of California, San Francisco and University of Michigan
  • Data to date shows the combination can be safely dosed and is clinically active
  • The trial has progressed to the efficacy stage and is progressing well
4. Phase 1b/2 trial in ovarian cancer in combination with immune checkpoint inhibitors nivolumab and ipilimumab:
  • The National Cancer Institute is conducting this trial in collaboration with Zenith and BMS
  • This is a second trial combining immune checkpoint inhibitors with ZEN-3694
  • The first patient is expected to be recruited in the first quarter of 2022
5. Phase 1b/2 trial in NUT carcinoma in combination with chemotherapy:
  • Produced in collaboration with the National Cancer Institute
  • Ultra-orphan indication with significant unmet need
  • The first patient should be recruited in the first half of 2022
6. Phase 1b/2 trial solid tumors and lymphomas in combination with entinostat:
  • The National Cancer Institute is conducting this trial in collaboration with Zenith and Syndax
  • The first patient should be recruited in the first half of 2022

About Zenith

Zenith Capital Corp. is a biotechnology investment company originally spun off from Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly owned subsidiary of Zenith Capital Corp., is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for the treatment of cancer and other disorders with significant unmet medical needs. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for various oncology indications, including: mCRPC in combination with the androgen receptor blocker, XTANDI; Triple negative breast cancer in combination with the PARP inhibitor TALZENNA; androgen receptor-independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI; Ovarian cancer in combination with immune checkpoint inhibitors nivolumab and ipilimumab; midline NUT carcinoma in association with chemotherapy; solid tumors and lymphomas in combination with ennostat.

For more information, please contact:

Investor relations and communication

Zenith Capital Corp.
Phone: 587-390-7865
Email: [email protected]
Website: www.zenithepigenetics.com

This press release may contain certain forward-looking information as defined by applicable Canadian securities laws that is not based on historical fact, including, without limitation, statements containing the words “believes”, ” anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continues”, “estimates”, “plans” and other similar expressions. In particular, this press release contains forward-looking information regarding the potential role of ZEN-3694 in the treatment of cancer and other disorders, and the company’s development of ZEN-3694, including its current and anticipated applications Clinical studies. Our actual results, events or developments could differ materially from those expressed or implied by these forward-looking statements. We cannot guarantee that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors, including those discussed in our most recent MD&A, which are incorporated herein by reference and are available on SEDAR at address www.sedar.com. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or liability, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share.

Comments are closed.